Endast för hälso-och sjukvårdspersonal

Produktresumé för våra godkända läkemedel på FASS:  Breyanzi® (lisokabtagen-maraleucel)

How can we improve outcomes for patients with R/R LBCL?

Duration: 3 minutes

Listen to Prof. Sirpa Leppä, Chair of the Nordic Lymphoma Group, as she discusses key focus areas for improving outcomes across different patient groups with aggressive B-cell lymphomas.

Related videos

Optimizing CAR-T Bridging Therapy in LBCL
Post-CAR-T treatment and outpatient setting

News

Learn about current topics in hematology, such as new research data, news from events, congresses and more.

Education

Find past and upcoming educational events and access learning tools such as webinars, training videos and expert interviews.

 

HE-SE-2400026 FEB25/ 2009-SE-2500035 01/2026